Markus Moehler

机构：University of Applied Sciences Mainz, Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz · ORCID：0000-0003-4071-8562

发表论文 63 篇 · 总被引 2340 次 · h-index 17

代表论文

• Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial (2024 · BMJ · 被引 266)
• Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer (2025 · New England Journal of Medicine · 被引 265)
• Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577. (2025 · Journal of Clinical Oncology · 被引 45)
• Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study (2025 · Journal of Clinical Oncology · 被引 36)
• PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays (2024 · JCO Precision Oncology · 被引 33)
• Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab (2025 · Modern Pathology · 被引 18)